Mostrando 5 resultados de: 5
Filtros aplicados
Publisher
Cell and Bioscience(1)
Expert Opinion on Investigational Drugs(1)
Frontiers in Aging Neuroscience(1)
Journal of Psychopharmacology(1)
Pharmaceuticals(1)
Área temáticas
Enfermedades(5)
Farmacología y terapéutica(2)
Fisiología humana(2)
Ginecología, obstetricia, pediatría, geriatría(1)
Medicina y salud(1)
Área de conocimiento
Farmacología(2)
Neurología(2)
Descubrimiento de fármacos(1)
Diabetes(1)
Medicamento(1)
Origen
scopus(5)
A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet
ArticleAbstract: Background: Alzheimer’s disease (AD) is characterized by a polyetiological origin. Despite the globaPalabras claves:Alzheimer’s disease, BACE1, BDNF, cognitive decline, dendritic spines, high-fat diet, neuroinflammation, Rhein-huprine hybrid, Tau, TLR4Autores:Antoni Camins, Auladell C., Bulló M., Cano A., Espinosa-Jimenez T., Ettcheto M., Folch J., Muñoz-Torrero D., Olloquequi J., Parcerisas A., Pont C., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusExcitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic implications
ReviewAbstract: Neurological and psychiatric disorders are leading contributors to the global disease burden, havingPalabras claves:Alzheimer’s disease, Autism Spectrum Disorder, Depression, glutamate, strokeAutores:Antoni Camins, Auladell C., Binvignat O., Cornejo-Córdova E., Olloquequi J., Soriano F.X., Verdaguer E.Fuentes:scopusMetformin a potential pharmacological strategy in late onset Alzheimer’s disease treatment
ReviewAbstract: Alzheimer’s disease (AD) is one of the most devastating brain disorders. Currently, there are no effPalabras claves:Alzheimer’s disease, AMP activated protein kinase AMPK, Beta amyloid, diabetes mellitus, Insulin Resistance, Metformin, Tau protein hyperphosphorylationAutores:Antoni Camins, Cano A., Ettcheto M., Javan M., Manzine P.R., Olloquequi J., Poor S.R., Sanchez-Lopez E.Fuentes:scopusTriple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer’s disease
ArticleAbstract:Palabras claves:Alzheimer’s disease, glucagon, glucagon-like peptide, glucose-dependent insulinotropic peptide, Type 2 DiabetesAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Castro-Torres R.D., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sureda F.X., Verdaguer E., Zárate C.B.Fuentes:scopusThe Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer’s Dementia
ReviewAbstract: Nowadays, Alzheimer’s disease (AD) is a severe sociological and clinical problem. Since it was firstPalabras claves:Alzheimer’s disease, Insulin Resistance, Mediterranean diet, neuroinflammation and neurodegeneration, obesity, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Casadesús G., Espinosa-Jimenez T., Ettcheto M., Folch J., García M.L., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopus